Cell Death News and Research

RSS

Structural study identifies unexpected cancer-regulating functions of MLL4 protein

The epigenetic modifier MLL4 has an unassuming name-the 4, for instance, indicates it's just one in a family of such modifiers.

13 Jul 2026

Experimental compound BA-101 overcomes chemotherapy resistance in glioblastoma

Scientists have identified a promising new strategy to tackle one of the biggest obstacles in treating glioblastoma, one of the most aggressive form of brain cancer: resistance to chemotherapy.

9 Jul 2026

Study identifies new target for Parkinson's disease neuroprotection

Parkinson's disease (PD) is the second most common form of neurodegenerative disease and afflicts more than ten million people worldwide. While current therapies address disease symptoms, they do not prevent the underlying neurodegeneration that drives the disease.

8 Jul 2026

Microbiome science merges with oncology for better cancer treatments

Cancer remains notoriously difficult to treat, partly because tumors co‑opt their surrounding environment, including the resident microbiota, to evade immune surveillance and resist conventional therapies.

7 Jul 2026

New R package advances multi-pathway cell death analysis

Announcing a new article publication in BIO Integration. The authors of this article developed CellDeathAnalysis (v0.4.0), an R package providing a unified framework for analyzing 14 cell death pathways in bulk RNA-seq data.

6 Jul 2026

Study identifies promising drug target to prevent neurodegenerative conditions

6 Jul 2026

Experimental drug shields nerve cells from damage caused by ALS

Amyotrophic Lateral Sclerosis, or ALS, received widespread awareness in the summer of 2014 thanks to an Ice Bucket Challenge. Millions of people participated in the challenge, drenching themselves in ice cold water to bring visibility to this devastating neurodegenerative disease and generate charitable donations for research.

3 Jul 2026

Evolutionary noncoding RNAs reveal new targets for cancer therapy

In cancer research, one person's junk is increasingly becoming another person's treasure. Scientists have now uncovered new evidence showing how recently evolved "junk DNA" genetic elements can become integrated into ancient cellular pathways that regulate cancer.

1 Jul 2026

Study potential new therapeutic strategy for patients with ATRX-mutant gliomas

A new study from researchers at The University of Texas MD Anderson Cancer Center has uncovered how one of the most common genetic alterations in glioma rewires the cancer cell genome to fuel tumor progression, suggesting a potential new therapeutic strategy for patients with ATRX-mutant gliomas.

1 Jul 2026

New AI framework outperforms conventional biomarkers in predicting cancer survival

Digestive system cancers, including hepatobiliary and gastrointestinal malignancies, remain a major global oncological burden. Although immune checkpoint inhibitors have changed the treatment landscape for some patients, their overall efficacy remains limited, with only about 15% to 30% of patients achieving durable clinical benefit.

1 Jul 2026

Review links iron-dependent cell death to pathogenesis of Friedreich's Ataxia

Published in the open-access journal Ferroptosis and Oxidative Stress, the review by Giovanni Cravin and Giorgio Cozza from the University of Padua examines the growing evidence linking ferroptosis to the pathogenesis of Friedreich's Ataxia (FRDA), a rare inherited neurodegenerative disease characterized by progressive neurological decline, cardiomyopathy, and premature mortality.

30 Jun 2026

New drug candidate reduces toxic protein clumps of Huntington's disease

An experimental drug has been shown to alleviate symptoms of Huntington's disease and extend lifespan in mouse models. Further studies are required to determine whether these results may also apply to humans.

29 Jun 2026

Lipid nanoparticles enhance immune response against lung cancer

Researchers at the University of Arizona R. Ken Coit College of Pharmacy have developed a new strategy that helps the immune system recognize and attack lung cancer tumors more effectively.

25 Jun 2026

Iron overload gradually increases neurons' vulnerability to neurodegeneration

Neurodegenerative diseases affect tens of millions of people worldwide. Among these, Alzheimer's and Parkinson's diseases are the most common; in the United States alone, the Alzheimer's Disease Association and Parkinson's Foundation report roughly 7 million people with Alzheimer's and another million with Parkinson's.

25 Jun 2026

Discovery of karyoptosis opens new therapeutic targets for Alzheimer's and frontotemporal dementia

Markers of a new mechanism for cell death, called karyoptosis, have been found in brains of patients with Alzheimer's disease and frontotemporal dementia (FTD).

25 Jun 2026

Microbes trigger cell death to boost cancer immunotherapy effectiveness

Traditional cancer treatments like chemotherapy and radiotherapy can induce immunogenic cell death (ICD), but their efficacy is often limited by drug resistance, severe off-target toxicity, and immune-related adverse events.

24 Jun 2026

Study reveals early immune clues to predict active tuberculosis risk

An early view of the immune response to bacteria in the lungs provides clues as to why some people keep TB in check, while others develop disease, suggesting new ways to intervene earlier and stop TB.

24 Jun 2026

Skin barrier monitoring predicts necrosis after skin flap surgery

Random-pattern skin flaps (RPSFs) receive blood mainly from small subcutaneous vessels rather than a defined axial vessel, leaving them vulnerable to ischemia and hypoxia after surgery.

23 Jun 2026

Statins may trigger muscle side effects by activating inflammatory danger signals

An experimental study in Science Advances shows that statins, primarily fluvastatin in these experiments, may promote low-level muscle myopathy by reducing isoprenoid-dependent protein prenylation rather than by cholesterol lowering. In primed muscle cells and mouse models, impaired YAP signaling, reduced glycolysis, NLRP3/caspase-1 activation, and nuclear FOXO accumulation increased atrogin-1, reduced protein synthesis, and weakened muscle function.

22 Jun 2026

Copper-induced cell death stimulates antitumor immune cell responses

A preclinical study from researchers at The University of Texas MD Anderson Cancer Center, published today in Cell, details a connection between the immune system and cuproptosis, a type of copper-induced cell death.

22 Jun 2026